![]() |
11th International AIDS ConferenceVancouver, British Columbia — July 7-12, 1996 |
Int Conf AIDS 1996 Jul 7-12; 11:18 (abstract no. Th.A.924)
Ascher MS, Krowka J, Gesner M, Sheppard H; Viral and Rickettsial Disease Laboratory, Berkeley, CA. Fax: (510) 540-2127. E-mail: mascher@hwl.cahwnet.gov.
OBJECTIVE: To determine if plasma levels of RANTES, macrophage inflammatory protein type I (MIP1alpha), and MIP1beta are correlated with HIV burden, the rate of disease progression, in vivo CD8+ lymphocyte levels or other markers of immune activation.
METHODS: Plasma or PBL from HIV-infected (HIV+) rapid-progressor (RP), non-progressor (NP), and HIV-seronegative (HIV-) participants of the San Francisco Men's Health Study were analyzed to determine viral burden (RNA copies/ml) by quantitative PCR (Roche Monitor Assay), chemotactic cytokines and beta2M by EIA, neopterin by RIA, and CD4+ or CD8+ cells expressing HLA-DR and/or CD38 by flow cytometry.
CONCLUSIONS: These studies show significant elevations in the levels of RANTES but not MIP1alpha or MIP1beta in response to HIV-1 infection. Our analyses, however, revealed no significant associations between levels of chemotactic cytokines and progression or known predictors of progression to AIDS. These findings in patients with dramatically different levels of virus burden and disease progression are not consistent with a major role for these chemotactic cytokines in the long-term control of viremia or protection against the progression of HIV disease.
960707
ThA924
Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.